Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Top Cited Papers
Open Access
- 29 September 2016
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 76 (1), 88-95
- https://doi.org/10.1136/annrheumdis-2016-210094
Abstract
Background Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor. Methods In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and inadequate response or intolerance to ≥1 conventional synthetic DMARDs were randomly assigned 1:1:1 to placebo or baricitinib (2 or 4 mg) once daily, stratified by region and the presence of joint erosions. Endpoint measures included American College of Rheumatology 20% response (ACR20, primary endpoint), Disease Activity Score (DAS28) and Simplified Disease Activity Index (SDAI) score ≤3.3. Results More patients achieved ACR20 response at week 12 with baricitinib 4 mg than with placebo (62% vs 39%, p≤0.001). Compared with placebo, statistically significant improvements in DAS28, SDAI remission, Health Assessment Questionnaire-Disability Index, morning joint stiffness, worst joint pain and worst tiredness were observed. In a supportive analysis, radiographic progression of structural joint damage at week 24 was reduced with baricitinib versus placebo. Rates of adverse events during the treatment period and serious adverse events (SAEs), including serious infections, were similar among groups (SAEs: 5% for baricitinib 4 mg and placebo). One patient had an adverse event of tuberculosis (baricitinib 4 mg); one patient had an adverse event of non-melanoma skin cancer (baricitinib 4 mg). Two deaths and three major adverse cardiovascular events occurred (placebo). Baricitinib was associated with a decrease in neutrophils and increases in low-density and high-density lipoprotein. Conclusions In patients with rheumatoid arthritis and an inadequate response or intolerance to conventional synthetic DMARDs, baricitinib was associated with clinical improvement and inhibition of progression of radiographic joint damage. Trial registration number NCT01721057; Results.Keywords
This publication has 23 references indexed in Scilit:
- A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor TherapyArthritis & Rheumatology, 2016
- Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trialAnnals Of The Rheumatic Diseases, 2013
- Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1Annals Of The Rheumatic Diseases, 2013
- Janus kinase inhibitors in autoimmune diseasesAnnals Of The Rheumatic Diseases, 2013
- Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity scoreArthritis Research & Therapy, 2005
- Assessment of radiographs in longitudinal observational studies.2004
- A simplified disease activity index for rheumatoid arthritis for use in clinical practiceRheumatology, 2003
- How to read radiographs according to the Sharp/van der Heijde method.2000
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.1982